Search
A vaccine to prevent rheumatic heart disease (RHD) and other life-threatening conditions caused by the common Strep A bacteria is a step closer thanks to funding announced by Minister for Indigenous Health, Hon Ken Wyatt AM, MP, in Perth today.
An international team of researchers has pioneered a technique which gives unprecedented insight into the dramatic changes occurring in a baby’s body in the first week of life.
Over 1000 Year 7 and 8 students from Churchlands Senior High School laced up their running shoes yesterday for their annual Fun Run raising money for the Wesfarmers Centre of Vaccines and Infectious Diseases.
The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.
Six weeks, nine community visits and 380 kids – it’s a wrap for round one of the StoP Trial!
Three The Kids researchers have been named amongst WA’s most outstanding young scientists for their efforts to ensure kids around the country have the chance to lead happy and healthy lives.
At just two years old, Lucy lost her fight against flu. With your generous help, we can finally beat influenza.
Risk-based recommendations are common for pneumococcal vaccines but little is known about their uptake. In Australia, pneumococcal conjugate vaccine (PCV) was funded only for Aboriginal or Torres Strait Islander (Indigenous) children and those with underlying medical conditions in 2001, and then there were different booster dose recommendations depending on risk after the introduction of universal PCV vaccination in 2005.
Small volume assays are required for large-scale research studies and in particular paediatric trials, where multiple measures are required from a single sample. Fluorescent bead-based technology (Bioplex/Luminex) allows high through-put and simultaneous quantification of multiple analytes in a single test. This technology uses sets of microspheres, each with a unique spectral address that can be coated with a different antigen of interest.
Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.